Stay updated with breaking news from Pascal Joly. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
JJP Biologics has received a positive conclusion on the Clinical Trial Application assessment for a Phase I Study of a potential first-in-class anti-CD89 antagonist, JJP-1212 monoclonal antibody for
JJP Biologics a private biopharmaceutical company developing innovative antibodybased therapies announces a positive decision issued by the European Medicines Agency on the Clinical Trial Application to conduct a phase I clinical study in healthy participants EudraCT 20235086613300 with their potential firstinclass antiCD89 antagonist JJP1212.
Methotrexate and low-dose prednisone combination outperformed methotrexate alone in patients with chronic and recalcitrant alopecia totalis and alopecia universalis, according to a study.Alopecia totalis (AT) and alopecia universalis (AU) are the most debilitating types of alopecia areata (AA) as they incur severe changes to a patient’s quality of life, according to Pascal Joly, MD, PhD, of
About 31% of patients with recalcitrant alopecia areata totalis or universalis had complete hair regrowth.